A three-pronged approach was followed for deducing the U.S. intravenous immunoglobulin market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:
Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for U.S. intravenous immunoglobulin market to gather the most reliable and current information possible.
Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of U.S. intravenous immunoglobulin market data depending on the type of information we’re trying to uncover in our research.
Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.
Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.
Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.
Qualitative Functional Deployment (QFD) Modelling for market share assessment.
Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.
Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.
Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.
This step also entails the finalization of the report scope and data representation pattern.
Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.
The U.S. intravenous immunoglobulin market was categorized into four segments, namely application (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Primary Immunodeficiency Diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, Immune Thrombocytopenia, Kawasaki Disease, Guillain-Barre Syndrome), distribution channel (Hospital Pharmacy, Specialty Pharmacy).
The U.S. intravenous immunoglobulin market was segmented into application, distribution channel. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:
Demand estimation of each product across countries/regions summed up to from the total market.
Variable analysis for demand forecast.
Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.
Primary interviews for data revalidation and insight collection.
Used extensively for new product forecasting or analyzing penetration levels.
Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.
Primary interviews and vendor-based primary research for variable impact analysis.
The U.S. intravenous immunoglobulin market was analyzed at a regional level.
All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.
The U.S. intravenous immunoglobulin market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:
Biotest AG - Biotest AG was established in 1946 and is headquartered in Germany. The company is engaged in development of innovative hematology, clinical immunology, and intensive care medicine products. It develops, produces, and markets plasma proteins & biotherapeutic drugs. It uses human blood plasma to produce immunoglobulins, coagulation factors, and albumins.
Octapharma AG - Octapharma AG is a Swiss-based private biotechnology company established in 1983. The company offers products for therapeutic areas, including immunotherapy, critical care, and hematology. It is one of the largest human protein product manufacturers and develops medicines based on human proteins from human cell lines. It has plasma donation centers and other external sources to receive blood plasma.
LFB Biotechnologies S.A.S - LFB Biotechnologies S.A.S is a France-based company founded in 1994. It is involved in R&D of monoclonal antibodies and one of the leading European companies providing hospital-based professionals with plasma-derived & recombinant medicinal products.
China Biologics Products Holdings, Inc. - China Biologics Products Holdings, Inc. is a biopharmaceutical company established in 2002 and headquartered in Beijing. The company is engaged in plasma collection, R&D, commercialization, and production of biopharmaceuticals.
Grifols, S.A. - Grifols, S.A. is a Spain-based healthcare company incorporated in 1940, and it is involved in marketing & distribution of biotechnological & pharmaceutical products. It primarily operates through four major divisions: bioscience, diagnostics, biosupplies, and hospitals. The company is also involved in providing medical products and services to medical & healthcare professionals in over 100 countries globally.
Kedrion S.p.A - Kedrion S.p.A is an international biopharmaceutical company established in 2001. It develops, manufactures, and commercializes lifesaving therapeutics derived from plasma. Its product offerings include immune deficiency products, orphan drugs, and products for hemophilia, and CIDP. It caters to therapeutic areas, including critical care, hematology, neurology, and immunology.
CSL - CSL is a U.S.-based company that manufactures & markets biotherapeutic products across the globe. The company offers a wide range of plasma-derived and recombinant products across the world. These products are used to treat coagulation disorders, including hemophilia & von Willebrand disease, primary immune deficiencies, certain neurological conditions, inherited respiratory disease, and hereditary angioedema.
Takeda Pharmaceutical Company Limited - Takeda Pharmaceutical Company Limited is a global research-based pharmaceutical company. It is one of the largest pharmaceutical companies in Japan. Its IBD treatment product, Entyvio, is approved in over 70 countries. Takeda’s drugs are marketed in around 100 countries worldwide. In 2019, the company acquired Shire to expand geographically.
BIO PRODUCTS LABORATORY LTD. - Bio Products Laboratory Ltd. or BPL ltd. is a UK-based company founded in 1954. It develops and manufactures plasma-derived products for healthcare industry. The company offers immunoglobulins, human coagulation factors, and albumin solutions for immunology, critical care, and coagulation disorders. It also produces a small volume of products for niche markets.
Pfizer, Inc.- Pfizer, Inc. is a multinational U.S.-based pharmaceutical company incorporated in 1849 and headquartered in New York, U.S. The company is involved in discovery, development, and manufacture of pharmaceutical products. It has a portfolio of vaccines and medicines. The company operates in two business segments: Essential Health (EH) and Innovative Health (IH).
Supply Side Estimates
Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.
Segment revenue determination via variable analysis and penetration modeling.
Competitive benchmarking to identify market leaders and their collective revenue shares.
Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.
Demand side estimates
Identifying parent markets and ancillary markets
Segment penetration analysis to obtain pertinent
Heuristic forecasting with the help of subject matter experts
Forecasting via variable analysis
Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.
Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.
Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 to 2020, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.
The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.
The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.
We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.
All market estimates and forecasts have been validated through primary interviews with the key industry participants.
Inflation has not been accounted for to estimate and forecast the market.
Numbers may not add up due to rounding off.
Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).
Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).
Latin America includes Central American countries and the South American continent
Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.
GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.
We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:
Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.
Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.
The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member